Clinical Trials
36 trialsRadiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
TraveraRTGx
Travera Inc
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Boehringer Ingelheim
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Hookipa Biotech GmbH
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
University of California, San Diego
ARROW
Hoffmann-La Roche
IT-01
Intensity Therapeutics, Inc.
KEYNOTE-B84
Vaccinex Inc.
Active MMP-8 in Oral Fluid for the Detection of Oral and Oropharyngeal Cancer
Helsinki University Central Hospital
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
M.D. Anderson Cancer Center
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
University of California, San Francisco
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Amgen
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
The University of Texas Health Science Center at San Antonio
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
SPICE
Akamis Bio
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
IMPACTHN
Liverpool University Hospitals NHS Foundation Trust
EPIC
University of Chicago
A Study in Advanced Solid Tumors
Eli Lilly and Company
Study in Advanced Solid Tumors
Eli Lilly and Company
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Massachusetts General Hospital
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
University of Chicago
B-Receptor Signaling in Cardiomyopathy
Stanford University
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
Sanofi
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Oncolytics Biotech
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Oncolytics Biotech
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
Merck KGaA, Darmstadt, Germany
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
University of Michigan Rogel Cancer Center
A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Pfizer
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
AstraZeneca
CLANC
Baylor College of Medicine
Phase II Trial of Allovectin-7® for Head and Neck Cancer
Vical